Cargando…
Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cogniti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488247/ https://www.ncbi.nlm.nih.gov/pubmed/37685872 http://dx.doi.org/10.3390/ijms241713064 |
_version_ | 1785103433831809024 |
---|---|
author | Inoue, Makoto Suzuki, Hideaki Meno, Kohji Liu, Shan Korenaga, Tatsumi Uchida, Kazuhiko |
author_facet | Inoue, Makoto Suzuki, Hideaki Meno, Kohji Liu, Shan Korenaga, Tatsumi Uchida, Kazuhiko |
author_sort | Inoue, Makoto |
collection | PubMed |
description | Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Using this system, we quantified plasma proteins using isotope-labeled synthetic peptides. A total of 192 patients, including 63 with AD, 71 with MCI, and 58 non-demented controls (NDCs), were analyzed. Multinomial regression and receiver operating characteristic (ROC) analyses were performed to identify specific combinations of plasma protein panels that could differentiate among NDCs, those with MCI, and those with AD. We identified eight plasma protein biomarker candidates that can be used to distinguish between MCI and AD. These biomarkers were associated with coagulation pathways, innate immunity, lipid metabolism, and nutrition. The clinical potential to differentiate cognitive impairment from NDC was assessed using area under the curve values from ROC analysis, which yielded values of 0.83 for males and 0.71 for females. This LC-MS-based plasma protein panel allows the pathophysiology of AD to be followed through detection of cognitive decline and disease progression markers. |
format | Online Article Text |
id | pubmed-10488247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104882472023-09-09 Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry Inoue, Makoto Suzuki, Hideaki Meno, Kohji Liu, Shan Korenaga, Tatsumi Uchida, Kazuhiko Int J Mol Sci Article Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Using this system, we quantified plasma proteins using isotope-labeled synthetic peptides. A total of 192 patients, including 63 with AD, 71 with MCI, and 58 non-demented controls (NDCs), were analyzed. Multinomial regression and receiver operating characteristic (ROC) analyses were performed to identify specific combinations of plasma protein panels that could differentiate among NDCs, those with MCI, and those with AD. We identified eight plasma protein biomarker candidates that can be used to distinguish between MCI and AD. These biomarkers were associated with coagulation pathways, innate immunity, lipid metabolism, and nutrition. The clinical potential to differentiate cognitive impairment from NDC was assessed using area under the curve values from ROC analysis, which yielded values of 0.83 for males and 0.71 for females. This LC-MS-based plasma protein panel allows the pathophysiology of AD to be followed through detection of cognitive decline and disease progression markers. MDPI 2023-08-22 /pmc/articles/PMC10488247/ /pubmed/37685872 http://dx.doi.org/10.3390/ijms241713064 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Inoue, Makoto Suzuki, Hideaki Meno, Kohji Liu, Shan Korenaga, Tatsumi Uchida, Kazuhiko Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title | Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title_full | Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title_fullStr | Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title_full_unstemmed | Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title_short | Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry |
title_sort | identification of plasma proteins as biomarkers for mild cognitive impairment and alzheimer’s disease using liquid chromatography–tandem mass spectrometry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488247/ https://www.ncbi.nlm.nih.gov/pubmed/37685872 http://dx.doi.org/10.3390/ijms241713064 |
work_keys_str_mv | AT inouemakoto identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry AT suzukihideaki identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry AT menokohji identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry AT liushan identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry AT korenagatatsumi identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry AT uchidakazuhiko identificationofplasmaproteinsasbiomarkersformildcognitiveimpairmentandalzheimersdiseaseusingliquidchromatographytandemmassspectrometry |